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Dear Editors,
We read with great interest the article by Angelo et al. in
CLINICS (1). This study revealed interesting points regard-
ing the impact of different genetic polymorphisms on
hepatitis C treatment efficacy in 181 Brazilian patients.
The evaluation of multiple genetic polymorphisms in this
study encouraged us to appreciate the authors’ attempt to
show the impact of host genetics on the treatment response
in hepatitis C virus (HCV)-infected Brazilian patients of
admixed ethnicity. Although the statistical analysis in this
study was comprehensive in its assessment of the associa-
tion between different genetic polymorphisms and treat-
ment response, we have several concerns about this
statistical analysis. We believe that the frequencies of the
polymorphism genotypes should have been reported for the
response groups instead of the polymorphisms genotypes
that were reported throughout the article. As a result, the
presentation of the frequencies of the polymorphism
genotypes in Table 2 would be preferable in vertical order
instead of in horizontal order (2). Additionally, the
protective genotype frequencies in the sustained virological
response group, which were presented in the abstract,
should be considered in the following manner: 44.2%
rs4969170 G/G; 17.3% rs2853744 T/T; 69.2% rs11730582 T/
T; 76.9% rs2071430 G/T; and 45.5% rs12979860 C/C. On the
other hand, data on the rs12979860 genotype were included
for 139 individuals in Table 2, and it appeared that the data
on the rs12979860 genotyping was missing for 42 patients in
this study. The authors reported that the frequency of
rs12979860 C/C was 18.8% in the study population, which
seems to be incorrect; considering the missing data in the
statistical calculation, we found the rs12979860 C/C
genotype frequency to be 24.5%. Another point that we
would like to address in this letter is that a multivariate
analysis should have been considered by the authors to
clarify the adjusted impact of each polymorphism alongside
other factors, such as liver fibrosis, on the response to
hepatitis C treatment (3). Finally, because the impact of
genetic factors on the HCV treatment response in popula-
tions with admixed ethnicity has been not well studied, a
study on a large sample of different ethnicities in regions
with an admixed population, such as Brazil, is highly
recommended. Each genetic marker could have an ethni-
city-specific influence on the response to hepatitis C
treatment, which should be investigated in a population-
based setting.
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